Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Tempus AI recently reported full-year 2025 results, with revenue rising to US$1.27 billion and net loss narrowing to US$245.03 million, alongside 83% year-over-year Q4 growth driven by diagnostics. At ...

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

According to a study by the American Cancer Society, only about 20% of eligible individuals in the United States underwent lung cancer screening in 2024. The report estimates that achieving full ...

Q4 2025 earnings call recap: 33%+ core growth, 69% Insights surge, $1.59B 2026 guide, $65M EBITDA, ASP upside—read now.

Strategic focus shifted from cautious spending and scaling to a full embrace of growth, especially with the 170% test volume growth target for 2026 and a doubling of sales reps. Guidance language ...

This paper reviews the relevant literature on students with disabilities in agriculture (education and employment) and aims to better inform future strategies in the agriculture sector. To assess ...

Priya Hays, Hays Documentation Specialists, LLC, discusses biomarker discovery through artificial intelligence and ...

March S&P 500 E-Mini futures (ESH26) are down -0.04%, andMarch Nasdaq 100 E-Mini futures (NQH26) are up +0.21% this morning as sentiment remains cautious following yesterday’s selloff on Wall Street ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

In a study with three UK academic institutions, the platform agreed with MDx results 94 percent of the time in detecting ...